csirt@kutim:~/threat-intel/cve/CVE-2026-33929

Katalog CVE

CVSS 4.3 · Medium EPSS 0,96%

Kerentanan Improper Limitation of a Pathname to a Restricted Directory ('Path Traversal') pada apache pdfbox. Skor CVSS 3.1 4.3 (Medium) menurut CISA ADP.

Deskripsi (NVD)

Improper Limitation of a Pathname to a Restricted Directory ('Path Traversal') vulnerability in Apache PDFBox Examples. This issue affects the ExtractEmbeddedFiles example in Apache PDFBox: from 2.0.24 through 2.0.36, from 3.0.0 through 3.0.7. Users are recommended to update to version 2.0.37 or 3.0.8 once available. Until then, they should apply the fix provided in GitHub PR 427. The ExtractEmbeddedFiles example contained a path traversal vulnerability (CWE-22) mentioned in CVE-2026-23907. However the change in the releases 2.0.36 and 3.0.7 is flawed because it doesn't consider the file path separator. Because of that, a user having writing rights on /home/ABC could be victim to a malicious PDF resulting in a write attempt to any path starting with /home/ABC, e.g. "/home/ABCDEF". Users who have copied this example into their production code should apply the mentioned change. The example has been changed accordingly and is available in the project repository.

Rincian

Terbit di NVD
14 April 2026
Terakhir diubah
17 Juni 2026
Status NVD
Analyzed
CVSS 3.1
4.3 (Medium), sumber CISA ADP
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:N/I:L/A:N · uraikan di kalkulator
Jenis kelemahan (CWE)
CWE-22: Improper Limitation of a Pathname to a Restricted Directory ('Path Traversal')
EPSS (30 hari)
0,96% peluang dieksploitasi; lebih tinggi dari 60,5% CVE lain

Produk dan versi terdampak

VendorProdukVersi terdampak
apache pdfbox Versi 2.0.24 hingga sebelum 2.0.37
apache pdfbox Versi 3.0.0 hingga sebelum 3.0.8

> Data dari konfigurasi CPE di NVD.

Referensi dan perbaikan

Sumber: NVD · CVE.org · EPSS. Halaman ini disusun otomatis dari data tersebut; pembaruan terakhir 5 Okt 2026, 20:11 WITA. Kalau sistem di Perangkat Daerah memakai produk ini dan butuh bantuan, laporkan lewat kanal pelaporan.